Effects of tranexamic acid on death, disability, vascular occlusive events and other morbidities in patients with acute traumatic brain injury (CRASH-3): a randomised, placebo-controlled trial. The CRASH-3 trial collaborators†
Investigators found that administering TXA within 3 hours of head trauma was associated with a 20% reduction in deaths among those with mild to moderate TBI, with no evidence of adverse effects or complications. The drug is more effective in less severely injured patients.
Published Lancet: October 14, 2019DOI:https://doi.org/10.1016/S0140-6736(19)32233-0
